case_images: PMC6965158_01
case_images: Waterfall plot of best overall response by week 24 for individual metastatic melanoma patients treated with high-dose IPI and high-dose IL-2. Bars represent the best overall response by week 24 as a percent change in tumor burden for each treated patient. Red bars denote patents with increased tumor burden, and green bars denote patients with decreased tumor burden.
case_images: fonc-09-01483-g0002.jpg
case_images: PMC6965158_01_fonc-09-01483-g0002.jpg
case_images: F2
case_images: Best overall response by week 24 was partial response in one patient (11%; 95% CI 0.57-43.5%) and stable disease in four patients (44%), with progressive disease in four patients (44%; Figure 2).
case_images: Peripheral blood HLA-DM:HLA-DO ratio and serum granzyme B are elevated in patients with decreased tumor burden following treatment with high-dose IPI and high-dose IL-2. The left panel shows the fold-change in HLA-DM:HLA-DO expression measured by flow cytometry within peripheral blood B cells (CD45+ CD19+ MHC-II+) of patients with an increase in tumor burden (n = 6) vs. patients with a decrease in tumor burden (n = 3). The right panel shows the fold-change in serum granzyme B over baseline (week 1) in patients with an increase in tumor burden (n = 6) vs. patients with a decrease in tumor burden (n = 3). Two-way ANOVA with Bonferroni correction; *P < 0.05 and **P < 0.01. Error bars represent S.E.M.
case_images: fonc-09-01483-g0003.jpg
case_images: PMC6965158_01_fonc-09-01483-g0003.jpg
case_images: F3
case_images: Granzyme B, a marker of cytolytic potential, and HLA-DM:HLA-DO ratio, a marker of antigen presentation capability, were significantly increased in patients with decreased tumor burden at weeks 12-24 (Figure 3).